Amarin Corporation Announces Greek Ministry Of Health Approval For National Reimbursement Of VAZKEPA To Reduce Cardiovascular Events In High-Risk Statin-Treated Adults
Portfolio Pulse from Benzinga Newsdesk
Amarin Corporation announced that the Greek Ministry of Health has approved national reimbursement for VAZKEPA, a drug aimed at reducing cardiovascular events in high-risk statin-treated adults.
May 28, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amarin Corporation received approval from the Greek Ministry of Health for national reimbursement of VAZKEPA, which is expected to reduce cardiovascular events in high-risk statin-treated adults.
The approval for national reimbursement in Greece is a significant milestone for Amarin Corporation, potentially increasing the market reach and sales of VAZKEPA. This positive regulatory news is likely to boost investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100